Risk factor
Very high price volatility
Profitability factor
Undervalued vs peers
About
Elevation Oncology, Inc., a clinical-stage biopharmaceutical company, focuses on developing therapeutics for the treatment of cancer in genomically defined patient populations in the United States. The company's lead program is the seribantumab, an anti-HER3 monoclonal antibody that is in Phase II CRESTONE trial for the treatment of advanced solid tumors harboring a neuregulin-1 fusion. Elevation Oncology, Inc. was incorporated in 2019 and is based in New York, New York.
Company Valuation
From both historical and forecast perspectives, the stock is underpriced compared to similar stocks. In particular, the stock is 'cheap' on EV/EBITDA.
Target Price
The average target price of ELEV is 0.40 and suggests 10% upside potential. Usually, this means a HOLD recommendation among investment firms. This neutral recommendation